Inhibrx Biosciences reported a net loss of $108.8 million for the nine months ended September 30, 2026, compared to $107.2 million in the prior year. The company significantly increased its cash position to $199.5 million following $175.0 million in debt proceeds, while its accumulated deficit grew to $355.0 million.
Inhibrx Biosciences reported Q3 2026 financial results, highlighting a cash position of $199.5 million and $2.0 million in revenue from a licensing agreement with Pfizer. The company is advancing its clinical pipeline, with upcoming data presentations for ozekibart in Ewing sarcoma and ongoing enrollment in the Phase 2 HexAgon study for ordastobart.
Inhibrx Biosciences CEO Mark Lappe Buys $832K of Stock
Mark Lappe, CEO, bought 9,840 shares of Inhibrx Biosciences, Inc. at $84.07 to $85.00 a share (average $84.54) in 4 transactions, worth $832K in total on Oct 14, 2026. Shares held after the trade: 169,900 (+1.5%).
Inhibrx Biosciences, Inc. has updated its corporate investor presentation, which is being used for meetings and conferences with the investment community. The presentation provides a summary of the company's business strategy and clinical pipeline updates for its investigational product candidates.